OXBDF - Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript

Oxford Biomedica Plc (OXBDF) Q4 2021 Earnings Conference Call April 20, 2022, 8:00 AM ET Company Participants Dr. Roch Doliveux – Chairman, Interim Chief Executive Officer Sophia Bolhassan – Director of Investor Relations Kyri Mitrophanous – Chief Scientific Officer Stuart Paynter – Chief Financial Officer Conference Call Participants Alistair Campbell – Liberum Myles Dixon – Peel Hunt Charles Weston – RBC Capital Markets Joseph Pantginis – H.C. Wainwright Julie Simmonds – Panmure Gordon Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Oxford Biomedica Preliminary Results 2021 conference call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. We will only be taking questions from the phone line today, and any questions submitted through the webcast will be answered after the call. As a reminder, today's conference call is being recorded. Sophia Bolhassan Welcome,

For further details see:

Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript